Impact of Beta-lactams on the Microbiota and Relative Fecal Abundance of Mulltidrug Resistant Bacteria
Enterobacterial Infection
About this trial
This is an interventional diagnostic trial for Enterobacterial Infection
Eligibility Criteria
Inclusion Criteria:
- age> 18
- ICU admitted patient
- rectal colonization of Enterobacteria
- accepting participation
- with medical insurance
Exclusion Criteria:
- patient without bacterial colonization
- under antibiotics more than 24hours
- without medical insurance
Sites / Locations
- Groupe Hospitalier Paris Saint Joseph
Arms of the Study
Arm 1
Experimental
Patients with ESBL, antibiotic pressure
Patients with ESBL, antibiotic pressure will be included. On the day of inclusion, a stool culture is performed on the first stool issued after the start of antibiotic therapy in order to evaluate the initial flora and the relative initial faecal abundance of multidrug-resistant bacteria. In the absence of stool emission by the patient, a rectal swab will be performed. 72 hours after initiation of antibiotic therapy, a blood sample (5 ml) will be taken to determine plasma concentrations of antibiotics. In addition, a stool sample will be taken at 72 hours after the start of antibiotic therapy, at the end of antibiotic therapy and 60 days after this end to evaluate the change in initial flora and relative faecal abundance of ESBL-producing enterobacteria.